Table 2.
Citation | Random sequence generation | Allocation concealment | Blinding (participants and personnel) | Blinding (outcome assessment) | Attrition | Selective reporting |
---|---|---|---|---|---|---|
Evans et al.38 | Unclear | Unclear | High risk | Unclear | Unclear | Unclear |
Feuille and Pargament39 | High risk | High risk | Unclear | Low risk | High risk | Unclear |
Forsyth and Hayes40 | Low risk | Unclear | High risk | Unclear | Low risk | Unclear |
Garland et al.41 | Low risk | Low risk | High risk | Unclear | Low risk | Unclear |
Liu et al.43 | Low risk | Low risk | Unclear | Low risk | High risk | Unclear |
Petter et al.44 | Unclear | Unclear | Unclear | Unclear | Low risk | Unclear |
Petter et al.45 | Low risk | Low risk | Unclear | Low risk | Low risk | Unclear |
Prins et al.46 | Unclear | Unclear | Unclear | Unclear | Low risk | Unclear |
Reiner et al.47 | Low risk | Low risk | Unclear | Unclear | Low risk | Unclear |
Sharpe et al.48 | Low risk | Unclear | Unclear | Unclear | Low risk | Unclear |
Swain and Trevena49 | Unclear | High risk | Unclear | Unclear | Unclear | Unclear |
Teixeira50 | Low risk | Low risk | High risk | Unclear | Low risk | Unclear |
Ussher et al.51 | Low risk | Unclear | Unclear | Unclear | Low risk | Unclear |
Warth et al.52 | Unclear | Low risk | High risk | Unclear | Low risk | Unclear |
Zeidan et al.55 | Unclear | Low risk | Unclear | Unclear | Low risk | Unclear |
Zeidan et al.56 | Low risk | Low risk | Unclear | Low risk | High risk | Unclear |
Cochrane Collaboration Tool: Higgins et al.31